Evidence map›Paper›PMID 40978029›Full record

ArticleFrontiers in oncology2025

Osthole suppresses prostate cancer progression by modulating PRLR and the JAK2/STAT3 signaling axis.

Linjun Yan, Jiaqi Mei, Yuanqiao He, Qi Cui, Xiaohong Wang, Feng Lv, Keyue Cao, Yuanjian Shao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Linjun YanSchool of Environmental and Biological Engineering, Nantong College of Science and Technology, Nantong, Jiangsu, China.
Jiaqi MeiDepartment of Hematology, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, China.
Yuanqiao HeCenter of Laboratory Animal Science, Nanchang University, Nanchang, Jiangxi, China.
Qi CuiSchool of Environmental and Biological Engineering, Nantong College of Science and Technology, Nantong, Jiangsu, China.
Xiaohong WangSchool of Environmental and Biological Engineering, Nantong College of Science and Technology, Nantong, Jiangsu, China.
Feng LvSchool of Environmental and Biological Engineering, Nantong College of Science and Technology, Nantong, Jiangsu, China.
Keyue CaoSchool of Environmental and Biological Engineering, Nantong College of Science and Technology, Nantong, Jiangsu, China.
Yuanjian ShaoSchool of Environmental and Biological Engineering, Nantong College of Science and Technology, Nantong, Jiangsu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Prostate cancer is a common malignancy in men with limited effective treatment options, highlighting an urgent need for novel therapeutic approaches. Osthole, a natural coumarin compound with antitumor properties, has shown potential in targeting various cancers. Methods: We conducted the study using a combination of network pharmacology, Results: Our findings revealed that Osthole significantly inhibited prostate cancer cell proliferation and migration in a dose-dependent manner and reduced tumor volume in Conclusion: These results collectively highlight the therapeutic potential of Osthole in targeting prostate cancer cells through PRLR and modulating the JAK2/STAT3 signaling pathway, warranting further clinical exploration.

Indexed as

JAK2/STAT3 pathwaynetwork pharmacologyostholePRLRprostate cancer

Identifiers

PMID40978029
PMCPMC12446008

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.